Filgrastim biosimilar - Biocon/Mylan

Drug Profile

Filgrastim biosimilar - Biocon/Mylan

Alternative Names: Nufil; Recombinant human granulocyte colony stimulating factor - Biocon

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Biocon
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants
  • Mechanism of Action Granulocyte colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 14 Oct 2013 Clinical trials in Neutropenia in European Union (IV)
  • 14 Oct 2013 Clinical trials in Neutropenia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top